Abstract
Abstract Craniopharyngioma is prone to recurrence despite aggressive surgery; repeated surgery and radiotherapy are associated with risks of pituitary insufficiency, visual inacuity and anopsia, and neurocognitive dysfunction, adversely affecting patients' activity of daily life and quality of life. In a recent clinical trial in the US, molecular targeted therapy with vemurafenib and cobimetinib has achieved excellent objective response rate in BRAF-mutant cranopharyngioma. We report a case of BRAF-mutant papillary craniopharyngioma refractory to multiple surgeries and radiosurgery that was successfully treated with encorafenib and binimetinib. Molecular targeted therapy with BRAF inhibitor and MEK inhibitor can be a treatment option for BRAF-mutant craniopharyngioma, even after multiple recurrences with surgeries and radiotherapy.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
